Puma CFO sells 9,386 shares under 10b5-1 plan

PUMA Biotechnology Chief Financial Officer Maximo F. Nougues sold 9,386 shares of common stock on July 6, 2026 in an open-market transaction at an average price of $8.263 per share.

Rhea-AI Filing Summary

PUMA Biotechnology Chief Financial Officer Maximo F. Nougues sold 9,386 shares of common stock on July 6, 2026 in an open-market transaction at an average price of $8.263 per share. After this sale, he directly holds 230,637 shares of the company’s common stock.

The transaction was executed under a pre-arranged Rule 10b5-1(c) sell-to-cover program, originally adopted on December 14, 2020, indicating it followed a preset trading plan rather than discretionary market timing.

Insider Trade Summary 10b5-1

Net Seller: 9,386 shares

Net Sell 1 txn

Insider NOUGUES MAXIMO F

Role Chief Financial Officer

Sold 9,386 shs ($78K)

Type	Security	Shares	Price	Value
Sale	Common Stock	9,386	$8.263	$78K

Holdings After Transaction: Common Stock — 230,637 shares (Direct)

Footnotes (1)

1. F1. Adoption date of referenced 10b5-1(c) sell to cover program is: 12-14-2020.

Key Figures

Shares sold: 9,386 shares Sale price per share: $8.263 per share Shares held after transaction: 230,637 shares +2 more

5 metrics

Shares sold 9,386 shares Open-market sale on July 6, 2026

Sale price per share $8.263 per share Average price for the July 6, 2026 sale

Shares held after transaction 230,637 shares Direct ownership after reported sale

Net shares sold 9,386 shares Net-sell direction in transaction summary

Rule 10b5-1 plan adoption date December 14, 2020 Adoption date of sell-to-cover trading program

Key Terms

Rule 10b5-1(c), open-market sale, sell to cover program, Form 4

4 terms

Rule 10b5-1(c) regulatory

"Adoption date of referenced 10b5-1(c) sell to cover program is: 12-14-2020."

Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

sell to cover program financial

"10b5-1(c) sell to cover program is: 12-14-2020."

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did PUMA Biotechnology (PBYI) report for its CFO?

PUMA Biotechnology reported that CFO Maximo F. Nougues sold 9,386 shares of common stock. The sale occurred on July 6, 2026, as an open-market transaction executed under a pre-arranged Rule 10b5-1(c) sell-to-cover trading program adopted in December 2020.

At what price did the PUMA Biotechnology (PBYI) CFO sell his shares?

The CFO sold 9,386 PUMA Biotechnology common shares at an average price of $8.263 per share. This was an open-market sale, reported on Form 4, and executed pursuant to a previously adopted Rule 10b5-1(c) sell-to-cover trading program.

How many PUMA Biotechnology (PBYI) shares does the CFO hold after the reported sale?

Following the July 6, 2026 transaction, CFO Maximo F. Nougues directly holds 230,637 shares of PUMA Biotechnology common stock. This post-transaction holding amount is disclosed in the Form 4 and reflects his remaining direct ownership position after the open-market sale.

Was the PUMA Biotechnology (PBYI) CFO trade made under a Rule 10b5-1 plan?

Yes. The Form 4 footnote states the sale was made under a Rule 10b5-1(c) sell-to-cover program adopted on December 14, 2020. Such pre-arranged trading plans schedule transactions in advance according to preset instructions rather than day-to-day market decisions.

How large was the PUMA Biotechnology (PBYI) CFO’s Form 4 sale in share terms?

The Form 4 shows an open-market sale of 9,386 shares of PUMA Biotechnology common stock. The transaction summary labels this as a net-sell event, with no corresponding purchases or option exercises reported in the same filing for that transaction date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/08/2026 - 08:18 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

NOUGUES MAXIMO F

(Last) (First) (Middle)

C/O PUMA BIOTECHNOLOGY, INC.

10880 WILSHIRE BLVD., SUITE 1700

(Street)

LOS ANGELES CALIFORNIA 90024

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PUMA BIOTECHNOLOGY, INC. [ PBYI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/06/2026		S(1)		9,386	D	$8.263	230,637	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Adoption date of referenced 10b5-1(c) sell to cover program is: 12-14-2020.

	/s/ Gordon Esplin as attorney-in-fact for Maximo F. Nougues	07/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)